BEIJING (Reuters) – Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China’s CanSino Biologics Inc and a military-backed research unit, clinical trial registry data showed.
A single dose of the vaccine candidate Ad5-nCoV, one among a handful that China is pursuing, has final-stage trials lined up in Pakistan and Russia. The candidate has been approved for use in the Chinese military.
Scientists outside the company have expressed concern that the effectiveness of Ad5-nCoV, which uses a common cold virus many people have contracted to carry genetic traces of the coronavirus, could be limited.
In response, CanSino said earlier this month there was no evidence that existing immunity against the common cold virus could severely hurt Ad5-nCoV’s ability to trigger antibodies against the new coronavirus, citing data gathered from a single dose-based Phase 2 trial.
In July, researchers working on Ad5-nCoV said a flexible additional dose might be able to provide enhanced immune response, based on their previous experience using this method to develop a common cold virus-based Ebola vaccine.
The new two-dose Phase 1 trial will test the safety of two doses and their ability to generate an immune response, showed a registration record published on Thursday. https://bit.ly/35Zzi4r
Researchers expect to recruit 168 healthy adults to take two doses of Ad5-nCoV for the trial estimated to begin on Sept. 20 in China’s Wuhan.
A CanSino representative declined to comment on the new trial.
(Reporting by Roxanne Liu and Tony Munroe; Editing by Christopher Cushing)
